Science watch

Our science watch section reports on the story behind the media-reported “breakthrough” headlines in dementia, by focusing on the original journal study. Reports of other developments in research on care and cure are also included.

10/05/2019		Jülich completes Phase I trial for its AD drug PRI-002
08/05/2019		The Food and Drug Administration (USA) provides Optina Diagnostics with breakthrough device designation for a new Retinal Imaging Platform
07/05/2019		Actinogen Medical announces results from its Phase II clinical trial XanADu in AD
07/05/2019		Merck presents positive Phase III data of BELSOMRA® (suvorexant) for the treatment of insomnia in AD
07/05/2019		Study suggests that spatial navigationability may help identify people at high genetic risk of developing AD
06/05/2019		Alector announces the recruitment of the first participant in Phase Ib trial of AL002 for AD
06/05/2019		Researchers link cognitive decline in Parkinson’s disease with genetic variants of AD
01/05/2019		High-resolution mapping of single brain cells from people with AD identifies early molecular drivers of disease
30/04/2019		Researchers publish new guidelines for Alzheimer’s disease-like condition
15/04/2019		Trials start for short iPad test to detect early signs of dementia
11/04/2019		Researchers publish study findings of the halted Phase III AD drug trial on verubecestat
07/04/2019		Study on mice aims to block gum disease-related bacteria from traveling into the brain to avoid the release of toxins that might be involved in the development of AD
03/04/2019		Amylyx Pharmaceuticals announces recruitment of first participants in a recently expanded Phase II trial of AMX0035 for AD
02/04/2019		Bill Gates announces new call for proposals for innovative Alzheimer’s diagnosis research projects
02/04/2019		The IDEAS study publishes results on the effect of amyloid PET imaging to improve clinical management in MCI and dementia

 

Next » 1 2 3 4 5 ...109